Emmes is excited to share the significant progress being made in clinical studies we undertake for clients and to give you a look inside some of our own news.
Emmes Announces Its Work on a Phase 3 Clinical Trial for Breakthrough Therapy Designation Product
Emmes today announced that it provided the Phase 3 clinical trial support for a new investigational cell therapy that offers a promising treatment opportunity for patients who need an allogeneic bone marrow transplant. Emmes’ work for Gamida Cell Ltd. , an advanced cell therapy company committed to finding cures for blood cancers and serious blood diseases, involved full scope clinical trial support for this study that was conducted at more than 50 centers in the United States, Latin America, Europe and Asia. Emmes also supported the early development Phase 1 and 2 trials that began in 2010.
Emmes Announces its Contribution to NIH ACTT Clinical Trial for Remdesivir
Emmes today announced that its data and statistical analysis work for the Adaptive COVID-19 Treatment Trial (ACTT) played an important role in the accelerated timetable to evaluate remdesivir’s effectiveness in treating hospitalized COVID-19 patients.
Emmes Ranked as a Top Biosciences Employer in Greater Washington
Emmes today announced that it was ranked as the seventh largest biosciences employer in the greater Washington area. The ranking is compiled annually by the Washington Business Journal. Emmes reported revenues of $125 million in 2019 and has more than 750 employees globally. More than 675 employees work in Maryland, Virginia and Washington, D.C.
Emmes today announced that Dr. Joe Sliman has been named the company’s chief medical officer (CMO)
According to Dr. Anne Lindblad, president and chief operating officer, “The depth and breadth of Joe’s biopharmaceutical and government experience will be extremely valuable in supporting both our government and commercial clients.”
Three Long-Time Emmes Employees Are Named VPs
Emmes today announced that Heather Hill, Dr. Adam Mendizabal and Dr. Nilay Shah have been promoted to vice president. According to Dr. Anne Lindblad, president and chief executive officer, “These promotions reflect their talent and value to the organization. Heather, Adam and Nilay demonstrate our commitment to developing staff and promoting from within. They will strengthen and add great value to our leadership team and will support our plans to grow both internally and externally.”
EU MDR may be postponed for 1 year
The EU Commission with the voice of Stefan De Keersmaecker announced that they are working on a proposal to postpone the EU MDR for 1 year.
Kathleen Wolf Joins Emmes as VP of Clinical Operations
Emmes today announced that Kathleen Wolf has joined the company as vice president of clinical operations. She has two decades of leadership experience in the biopharmaceutical industry, including most recently as a senior director with AstraZeneca’s MedImmune unit. Dr. Anne Lindblad, president and chief executive officer of Emmes, said, “Kathleen is an outstanding addition to our leadership team. Her background in both biotech and pharmaceutical settings will be a great asset. Her experience in building collaborative, cross-functional teams complements our clinical operations platform.”
CEE countries react to COVID 19
Overview of how regulators in selected CEE countries react to COVID 19 pandemic
NEOX operations during SARS CoV 2
Service to our valued clients is and remains uninterrupted
Emmes Study Leads to Pediatric Drug Labeling Change for Ampicillin
Emmes today announced that the Food and Drug Administration (FDA) has extended the labeling of ampicillin, a commonly used antibiotic, to include use in infants younger than 28 days in the treatment of serious conditions meningitis and septicemia. FDA’s approval was based in part on a National Institute of Child Health and Human Development (NICHD)-funded study, conducted under the Best Pharmaceuticals for Children Act (BPCA).
Emmes Studies Contribute to FDA Approval of a Medical Device That Estimates the Weight of Infants
Emmes today announced that the U.S. Food and Drug Administration (FDA) has approved a prescription-only medical device used to estimate the weight of infants who are up to 90 days of age.
Emmes Will Support Development of a New Universal Flu Vaccine for The National Institute of Allergy and Infectious Diseases
Emmes today announced that it is part of a team of medical centers, universities and private industry supporting the development of a “universal influenza vaccine” that could provide longer-lasting protection than current vaccines and combat a wider variety of influenza viruses.